Immunotherapy More Effective in Men: Study – The Scientist
The Scientist |
Immunotherapy More Effective in Men: Study
The Scientist While the immunotherapies boosted the chances for survival for men and women compared to patients who didn’t receive them, men saw a greater benefit. The hazard ratio, which describes the risk of dying, was 0.86 for women on checkpoint inhibitor … |
|
Rocket Pharmaceuticals (RCKT) Highlights Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102
StreetInsider.com Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced the presentation of updated data from the ongoing Phase 1/2 clinical trial of RP-L102, the Company’s lead lentiviral vector (LVV)-based gene therapy, for Fanconi Anemia (FA). The data were … |
Medscape |
Trial ‘Desperately Needed’ to Sequence Immunotherapy and Chemo in Lung Cancer
Medscape Skeptics might argue that the study was not necessarily concurrent versus sequential, but rather 100% of people getting chemotherapy and immunotherapy versus 50% of patients getting chemotherapy and immunotherapy. We have this option available, and … |